drugset / Trial / NCT07223138
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
NaSingle-groupOpen-labelTreatment
Summary
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
Timeline
- Start
- 2025-11-13
- Primary completion
- 2028-02-04
- Completion
- 2028-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M1095 | Protein / enzyme biologic | 60 mg | Subcutaneous |